Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06690827 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Clinical Trial of CD123-targeted CAR-NK Therapy for Relapse/Refractory AML or BPDCN

Name: Clinical Trial of CD123-targeted CAR-NK Therapy for Relapse/Refractory AML or BPDCN — clinical trial record (NCT06690827)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 1

SponsorChongqing Precision Biotech Co., Ltd

Started2024-12-12

View on ClinicalTrials.gov ↗

Amendment history

2026-08-26

Study Identification, Study Status, Oversight, Conditions v1

Primary completion moved earlier: 2027-10-30 → 2027-06-30

Completion date2028-10-30→2028-10-31

Start dateestimated 2024-11-13→confirmed 2024-12-12

Study titlerevised

Clinical Trial of CD123-targeted CAR-NK Therapy for Relapse/~~refractory~~Refractory AML or BPDCN

2024-11-13

Original filing

Chongqing Precision Biotech Co., Ltd

36 trials monitored

See 1 trial at risk

Leukemia

2,553 trials monitored

See 134 trials at risk

Acute Myeloid Leukemia (AML)

1,196 trials monitored

See 63 trials at risk

This is a clincal trial initiated by investigator to evaluate the safety and efficacy of anti-CD123 CAR-NK in the treatment of patients with relapsed/refractory acute myeloid leukemia or blastic plasma cell like dendritic cell tumors.

Trial Details

NCT Number	NCT06690827
Lead Sponsor	Chongqing Precision Biotech Co., Ltd
Conditions	AML (Acute Myeloid Leukemia), BPDCN (Blastic Plasmacytoid Dendritic Cell Neoplasm)
Enrollment	30 participants
Start Date	2024-12-12
Primary Completion	2027-06-30 (estimated)
Study Completion	2028-10-31 (estimated)
Updated on ClinicalTrials.gov	2026-08-28